# Lexicon Pharmaceuticals

Lexicon Pharmaceuticals is an Asset Manager based in The Woodlands, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** The Woodlands, United States
- **Region:** North America
- **Address:** The Woodlands, TX, United States
- **Founded:** 1995
- **Assets under management:** Undisclosed
- **Website:** lexpharma.com
- **LinkedIn:** https://www.linkedin.com/company/lexicon-pharmaceuticals

## Regulatory record

- **Reports private funds:** No

## About

Lexicon Pharmaceuticals was founded in 1995 in The Woodlands, Texas, originally building its pipeline from a large-scale mouse gene-knockout platform. Under former CEO Arthur Sands, the company transitioned from a technology platform into a drug-development organization, advancing small molecules targeting serotonin and sodium-glucose transport. That program produced sotagliflozin, a dual SGLT1/SGLT2 inhibitor for type 1 diabetes and heart failure, which the company partnered with Sanofi in 2015 in a deal valued up to $1.7 billion (public record). Sanofi terminated the partnership in 2019 after an FDA advisory committee voted against the drug in type 1 diabetes, leaving Lexicon to fund remaining development alone and later filing suit against its former partner. Lexicon's strategy now hinges entirely on sotagliflozin's commercial trajectory. After receiving an FDA complete response letter for the heart failure indication in 2019, the company refiled with a narrower label focused on heart failure in adults with type 2 diabetes and ultimately won approval in May 2023 for a broad heart failure population. The drug launched under the brand name Inpefa, positioning Lexicon as a rare small-cap biotech with its own commercial team. In April 2025, the board appointed Mike Exton as CEO, replacing Lonnel Coats, signaling a pivot toward M&A readiness or operational restructuring. The pipeline otherwise contains LX9211, a neuropathic pain candidate, and early-stage programs with no near-term catalysts. Lexicon employs a lean operational footprint in Texas without disclosed offices abroad. The company's scale is measured in enterprise value, not AUM—its market capitalization has fluctuated below $300 million following the Sanofi fallout (per public filings). Lexicon operates no family-office structure, no club-deal vehicles, and no philanthropic arm. It does not take outside capital beyond public equity markets and a limited history of royalty-based financing. The April 2025 CEO change marked the most significant governance event in years, arriving alongside board pressure to unlock value from a single approved product with unproven commercial uptake. Lexicon's defining structural quirk is its status as a publicly traded biotech that behaves, in risk terms, like a binary option on one drug. Unlike diversified pharma or platform biotechs with broad pipelines, Lexicon's fate ties to Inpefa's prescription numbers and payer coverage decisions. The company's post-Sanofi history—a terminated blockbuster partnership, a rare disease pivot, and a boardroom shakeup—makes it a case study in how a single-asset biotech can survive, but not necessarily thrive, as a public company.

## Sectors

- Healthcare Services

## People

- Mike Exton — Chief Executive Officer and Director

## Questions

### Who runs investment decisions at Lexicon Pharmaceuticals?

Lexicon is not an investment firm. It is an operating public company, and resource allocation decisions rest with CEO Mike Exton and the board of directors. The company deploys capital toward clinical development and commercialization of its own drug assets rather than third-party investments.

### How did Lexicon lose its partnership with Sanofi?

Sanofi terminated a 2015 collaboration agreement in July 2019 after an FDA advisory committee voted against approving sotagliflozin for type 1 diabetes. The termination returned full rights to the drug to Lexicon, which then sued Sanofi. The companies settled in 2020 with Sanofi paying $260 million to Lexicon (public record).

### Why did the board replace the CEO in April 2025?

Lexicon's board appointed Mike Exton as CEO in April 2025, replacing Lonnel Coats, who had led the company since 2021. The change came amid pressure to accelerate Inpefa's commercial performance and evaluate strategic alternatives, including a potential sale or reverse merger.

## Related profiles

- [BlackRock MuniHoldings California Quality Fund](https://altss.com/profile/blackrock-muniholdings-california-quality-fund-inc)
- [Kayne Anderson BDC](https://altss.com/profile/kayne-anderson-bdc-inc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/lexicon-pharmaceuticals-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology